Tdk Corporation

Daiichi Sankyo Company, Limited

Dai Nippon Printing Co., Ltd.

Mie University

Pieris Pharmaceuticals Gmbh

National Institute of Advanced Industrial Science and Technology

Headway Technologies, Incorporated

Daiichi Pharmaceutical Co., Ltd.

Ryuji Hashimoto

Kenichi Suzuki

Kyung-Ku Choi

Yasushi Enokido

Tohru Takahashi

Andrea Allersdorfer

Christine Rothe

Marlon Hinner

Alexander Wiedenmann

Gabriele Matschiner

Rachida Siham Bel Aiba

Bradley Lunde

Daisuke Nishimiya

Mamoru Otoyo

Kensuke Nakamura

Akio Ogawa

Shinji Yamaguchi

Andreas Hohlbaum

Hiroshi Shiku

Hitomu Watanabe

Masashi Ito

Futoshi Nara

Toshiaki Ohtsuka

Yuji Umeda

Kenta Takagi

Ichiro Watanabe

Kazufumi Kubota

Kenichi Nishikawa

Makiko Nakayama

Kento Tanaka

Naoya Shinozaki

Hidenori Yano

Tsutomu Chikamatsu

Tomohiro Nishizawa

Shiho Kozuma

Junya Ichikawa

Shusuke Okada

Yasushi Akahori

Sakiko Takahashi

Makoto Kimura

Ayaka Yatsu

Shinji Furuzono

Yoichi Niitsu

Takahide Aburatani

Chikako Nagasaki

Mitsuhiro Makino

Yoshitaka Sasaki

Hiroyuki Ito

Daisuke Tanaka

Takashi Watanabe

Yoshinori Fujikawa

Tatsuya Harada

Nobuyuki Okuzawa

Toshiyuki Sato

Takako Kimura

Masaki Tomita

Tatsuya Inoue

Yuki Nagamine

Taku Masai

Satoru Sueki

Keiji Takeda

Nobuo Machinaga

Yasuhiro Doi

Takurou Iwasa

Jun Chiba

Eiichiro Fukuchi

Nobuyuki Higashihashi

Katsuichi Sakano

Shogo Kadota

Hironori Wada

Junya Yamada

Toshihito Shimizu

Ryotaku Inoue

Kyung-Kun Choi

Atsushi Yamasaki

A functional filmaccording to an embodiment includes: a substrate () containing an acetyl cellulose resin; a primer layer () containing a filler () and disposed on the substrate (); and a functional layer () containing the filler () and disposed on the primer layer (). The substrate () has a permeation layer () formed by permeation of the resin contained in the primer layer () into part of the substrate (). The permeation layer () has a thickness of 0.1 μm or more and 3.5 μm or less. The primer layer () has a thickness of 0.1 μm or more and 1.0 μm or less. The filler () is silica particles having an average particle size of 20 nm or more and 80 nm or less. The filler () in the primer layer () has a density of ⅓ or more and ¾ or less of the density of the filler () in the functional layer (). The primer layer () and the functional layer () each contain a resin. The resin component of the primer layer () is the same as the resin component of the functional layer

Functional film and method for producing same

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Conjugate comprising an active MMP-9-binding peptide

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Active MMP9-binding peptide

One embodiment of the present invention includes, in a samarium-iron-nitrogen based magnet powder, a main phase containing samarium and iron, and a sub-phase containing samarium, iron, and at least one or more elements selected from the group consisting of zirconium, molybdenum, vanadium, tungsten, and titanium, wherein an atomic ratio of a rare earth element to an iron group element is greater than an atomic ratio of the rare earth element to the iron group element of the main phase, wherein at least a part of a surface of the main phase is coated with the sub-phase.

Samarium-iron-nitrogen based magnet powder and method of manufacturing same, and samarium-iron-nitrogen based magnet and method of manufacturing same

One embodiment of the present invention is that in samarium-iron-nitrogen magnet powder, a non-magnetic phase is formed on a surface of the samarium-iron-nitrogen magnet phase, and an arithmetic mean roughness Ra of the surface is 3.5 nm or less.

Samarium-iron-nitrogen magnet powder and method for manufacturing same

A permanent magnet including R and T. R are rare earth elements including Sm and at least one selected from Y and Gd. T is Fe alone or Fe and Co. T maybe partly substituted with M, and M is one or more selected from Ti, V, Cr, Mo, W, Zr, Hf, Nb, Ta, Al, Si, Cu, Zn, Ga and Ge. In a total content of R, Sm content is 60 at % or more and 95 at % or less, and a total content of Y and Gd is 5 at % or more and 35 at % or less. The permanent magnet includes main phase crystal grains having a ThMntype crystal structure.

Permanent magnet

Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.

Peptide library and use thereof

To provide a rare earth permanent magnet having as a main phase a compound with a NdFecrystalline structure having strong coercive force. A rare earth permanent magnet having as a main phase a compound with a NdFecrystalline structure, wherein when the composition ratio of the rare earth permanent magnet is expressed as RTC, where R is one or more rare earth elements requiring Sm, and T is one or more transition metal elements requiring Fe or Fe and Co, a and b satisfy 18&#x3c;a&#x3c;40 and 0.5&#x2264;b, and a phase where R and C are denser than the main phase is provided in the grain boundary phase of the rare earth permanent magnet.

Rare-earth permanent magnet

A rare-earth sintered magnet contains main phase crystal grains having an Nd5Fe17-type crystal structure, includes R and T (where R represents one or more rare-earth elements that essentially include Sm and T represents Fe or one or more transition metal elements that essentially include Fe and Co), and wherein the compositional ratio of R is 20-40 at % and the remaining portion is substantially T; the remaining portion other than R is substantially only T or only T and C; and when the main phase crystal grains' average grain size in one cross-sectional surface of the rare-earth sintered magnet is defined as Dv, while grain size of individual main phase crystal grains is defined as Di, Dv is at least 1.0 &#x3bc;m, and the main phase crystal grains' area ratio that satisfy 0.7Dv&#x2264;Di&#x2264;2.0Dv is at least 80% with respect to the area of a cross-sectional surface of the rare-earth sintered magnet.

Rare-earth sintered magnet

The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Proteins specific for calcitonin gene-related peptide

To provide a permanent magnet which uses Ce of an abundant resource and has a great magnetic anisotropy in rare earth permanent magnets. To obtain a permanent magnet having a high magnetic anisotropy due to the trivalent Ce state by setting the abundance ratio C3/(C3+C4) in the main phase grains to be 0.1&#x2264;C3/(C3+C4)&#x2264;0.5 where C3 denotes the number of trivalent Ce atoms and C4 denotes the number of tetravalent Ce atoms.

Growing community of inventors

Tokyo, Japan

Ryuji Hashimoto